Finally further research is needed to develop new risk stratification tools for disease progression/PCa mortality based on new grade classifications in combination with other clinical characteristics, e.g. diagnostic PSA levels, to provide patients and clinicians with more refined risk-based information to guide treatment decisions. This evidence concerns the gene KLK3 and posterior cortical atrophy.